Therapy Areas: Inflammatory Diseases
Leronlimab 14-Week, NASH Clinical Trial Met Primary Endpoint and Secondary Endpoint for Per Protocol Population in 350 mg Weekly Dose
Login
Username:

Password:


Related Headlines